I. Executive Summary and Scope The $1.6 trillion global pharmaceutical industry runs on a single underlying premise: time-limited exclusivity justifies […]

Executive Summary Generic drugs now account for roughly 90% of all U.S. prescriptions filled, yet constitute less than 13% of

A deep-dive for pharma/biotech IP strategists, pipeline analysts, and buy-side investors. Part I: The Japanese Pharmaceutical Market Sizing Up the

The pharmacy counter is one of the most consequential decision points in American healthcare. A prescription that a physician deemed

Who this is for: Pharma and biotech IP teams, portfolio managers, R&D leads, M&A counsel, and institutional investors with exposure

Section I: The Economic Architecture of Pharmaceutical Patents The 20-Year Fiction: Why Statutory Term and Commercial Life Are Two Different

Who this is for: Pharma and biotech IP counsel, portfolio managers, R&D leads, generic drug strategy teams, business development executives,

A comprehensive framework covering due diligence, KPI architecture, IP asset valuation, technology roadmaps, and strategic governance across the full drug

When generic competition arrives, it arrives fast. Within the first 12 months of a major brand losing exclusivity, generic entrants